CL2019001512A1 - Tratamiento de enfermedades neurológicas. - Google Patents
Tratamiento de enfermedades neurológicas.Info
- Publication number
- CL2019001512A1 CL2019001512A1 CL2019001512A CL2019001512A CL2019001512A1 CL 2019001512 A1 CL2019001512 A1 CL 2019001512A1 CL 2019001512 A CL2019001512 A CL 2019001512A CL 2019001512 A CL2019001512 A CL 2019001512A CL 2019001512 A1 CL2019001512 A1 CL 2019001512A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- neurological diseases
- glp
- disease
- gip
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Peptides Or Proteins (AREA)
Abstract
LOS ASPECTOS Y MODALIDADES DE LA PRESENTE INVENCIÓN SE REFIEREN AL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS TALES COMO, POR EJEMPLO, ENFERMEDAD DE ALZHEIMER Y ENFERMEDAD DE PARKINSON. PARTICULARMENTE, DETERMINADAS MODALIDADES SE REFIEREN A PÉPTIDOS COAGONISTAS DE GIP/GLP-1 PARA USAR EN EL TRATAMIENTO DE ESTOS DOS TRASTORNOS NEUROLÓGICOS. TAMBIÉN SE INCLUYEN EN LA PRESENTE INVENCIÓN, ENTRE OTRAS, COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS PÉPTIDOS COAGONISTAS DE GIP/GLP-1, JUNTO CON LOS MÉTODOS PARA TRATAR DICHOS TRASTORNOS ASÍ COMO TAMBIÉN OTRA MATERIA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1620611.2A GB201620611D0 (en) | 2016-12-05 | 2016-12-05 | Treatment of neurological diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019001512A1 true CL2019001512A1 (es) | 2019-11-22 |
Family
ID=58159786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019001512A CL2019001512A1 (es) | 2016-12-05 | 2019-06-04 | Tratamiento de enfermedades neurológicas. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11220534B2 (es) |
| EP (1) | EP3548061B1 (es) |
| JP (1) | JP7099729B2 (es) |
| KR (1) | KR102600128B1 (es) |
| CN (1) | CN110312520B (es) |
| AU (1) | AU2017371811B2 (es) |
| BR (1) | BR112019011462A2 (es) |
| CA (1) | CA3044797A1 (es) |
| CL (1) | CL2019001512A1 (es) |
| CO (1) | CO2019006979A2 (es) |
| CY (1) | CY1123623T1 (es) |
| DK (1) | DK3548061T3 (es) |
| ES (1) | ES2833408T3 (es) |
| GB (1) | GB201620611D0 (es) |
| HR (1) | HRP20201959T1 (es) |
| HU (1) | HUE052766T2 (es) |
| LT (1) | LT3548061T (es) |
| MX (1) | MX2019006495A (es) |
| PT (1) | PT3548061T (es) |
| RS (1) | RS61230B1 (es) |
| RU (1) | RU2755997C2 (es) |
| SI (1) | SI3548061T1 (es) |
| SM (1) | SMT202000684T1 (es) |
| WO (1) | WO2018104718A1 (es) |
| ZA (1) | ZA201903003B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201620611D0 (en) * | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
| TW202140058A (zh) * | 2020-01-30 | 2021-11-01 | 美商美國禮來大藥廠 | 提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途 |
| WO2022018186A1 (en) | 2020-07-22 | 2022-01-27 | Novo Nordisk A/S | Co-agonists at glp-1 and gip receptors suitable for oral delivery |
| WO2022065897A1 (ko) * | 2020-09-25 | 2022-03-31 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 신경퇴행성 질환의 치료 용도 |
| CN114617956B (zh) * | 2020-12-10 | 2023-10-03 | 江苏中新医药有限公司 | 一种高效降糖的蛋白质药物 |
| CN114042149B (zh) * | 2021-12-03 | 2023-06-16 | 中国人民解放军空军军医大学 | D-Ala2-GIP用于制备治疗焦虑症药物的应用 |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| WO2023151594A1 (en) * | 2022-02-11 | 2023-08-17 | Hangzhou Sciwind Biosciences Co., Ltd. | A composition comprising gip receptor agonists and glp-1 receptor agonists and use thereof |
| WO2024209050A1 (en) | 2023-04-05 | 2024-10-10 | Antag Therapeutics Aps | Gip activity modulators and orthostatic intolerance |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2913056A1 (en) * | 2006-01-05 | 2015-09-02 | The University of Utah Research Foundation | Methods and compositions related to improving properties of pharmacological agents targeting nervous system |
| CN104945500B (zh) | 2008-06-17 | 2019-07-09 | 印第安纳大学研究及科技有限公司 | 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症 |
| EP2346906A4 (en) * | 2008-10-15 | 2013-04-24 | Angiochem Inc | CONJUGATES FROM GLP-1 AGONISTS AND THEIR USE |
| EP2528618A4 (en) | 2010-01-27 | 2015-05-27 | Univ Indiana Res & Tech Corp | GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS |
| DK2621945T3 (en) | 2010-09-28 | 2018-05-22 | Nono Inc | ND2 PEPTIDES AND METHODS OF TREATING NEUROLOGICAL DISEASE |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| US9579358B2 (en) | 2011-10-10 | 2017-02-28 | Lancaster University Business Enterprises Limited | Compositions for binding to amyloid proteins |
| TWI689515B (zh) * | 2012-05-03 | 2020-04-01 | 丹麥商西蘭製藥公司 | Ｇｉｐ-ｇｌｐ-１雙重促效劑化合物及方法 |
| TWI599575B (zh) * | 2012-06-21 | 2017-09-21 | 印第安納大學科技研究公司 | 表現ｇｉｐ受體活性之胰高血糖素類似物 |
| CN114057895A (zh) * | 2014-05-28 | 2022-02-18 | 诺诺公司 | TAT-NR2B9c的氯盐 |
| GB2528436A (en) * | 2014-07-15 | 2016-01-27 | Lancaster Univ Business Entpr Ltd | Treatment of neurological diseases |
| US20160143920A1 (en) * | 2014-10-22 | 2016-05-26 | Morris Notelovitz | Composition, formulations and methods of making and using botanicals and natural compounds for the promotion of healthy brain aging |
| US20170112897A1 (en) | 2015-10-23 | 2017-04-27 | Cedars-Sinai Medical Center | Methods for treating brain insulin resistance |
| JP2019504106A (ja) | 2015-10-28 | 2019-02-14 | タフツ ユニバーシティー | タンパク質分解安定性が改善された新規ポリペプチド並びにその調製方法及び使用方法 |
| WO2017210168A1 (en) | 2016-06-02 | 2017-12-07 | Indiana University Research And Technology Corporation | Aqueously soluble and chemically stable depsi glucagon agonists |
| GB201620611D0 (en) * | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
-
2016
- 2016-12-05 GB GBGB1620611.2A patent/GB201620611D0/en not_active Ceased
-
2017
- 2017-12-04 CN CN201780075565.8A patent/CN110312520B/zh active Active
- 2017-12-04 WO PCT/GB2017/053655 patent/WO2018104718A1/en active Application Filing
- 2017-12-04 LT LTEP17811693.5T patent/LT3548061T/lt unknown
- 2017-12-04 RU RU2019118165A patent/RU2755997C2/ru active
- 2017-12-04 HU HUE17811693A patent/HUE052766T2/hu unknown
- 2017-12-04 US US16/466,194 patent/US11220534B2/en active Active
- 2017-12-04 SM SM20200684T patent/SMT202000684T1/it unknown
- 2017-12-04 JP JP2019529926A patent/JP7099729B2/ja active Active
- 2017-12-04 BR BR112019011462A patent/BR112019011462A2/pt unknown
- 2017-12-04 MX MX2019006495A patent/MX2019006495A/es unknown
- 2017-12-04 AU AU2017371811A patent/AU2017371811B2/en active Active
- 2017-12-04 ES ES17811693T patent/ES2833408T3/es active Active
- 2017-12-04 EP EP17811693.5A patent/EP3548061B1/en active Active
- 2017-12-04 SI SI201730543T patent/SI3548061T1/sl unknown
- 2017-12-04 PT PT178116935T patent/PT3548061T/pt unknown
- 2017-12-04 DK DK17811693.5T patent/DK3548061T3/da active
- 2017-12-04 RS RS20201491A patent/RS61230B1/sr unknown
- 2017-12-04 CA CA3044797A patent/CA3044797A1/en active Pending
- 2017-12-04 KR KR1020197015601A patent/KR102600128B1/ko active Active
-
2019
- 2019-05-14 ZA ZA2019/03003A patent/ZA201903003B/en unknown
- 2019-06-04 CL CL2019001512A patent/CL2019001512A1/es unknown
- 2019-06-27 CO CONC2019/0006979A patent/CO2019006979A2/es unknown
-
2020
- 2020-12-07 HR HRP20201959TT patent/HRP20201959T1/hr unknown
- 2020-12-09 CY CY20201101167T patent/CY1123623T1/el unknown
-
2021
- 2021-10-13 US US17/500,430 patent/US11851468B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001512A1 (es) | Tratamiento de enfermedades neurológicas. | |
| CO2018012482A2 (es) | Formulaciones de un inhibidor de lsd1 | |
| CO2018009889A2 (es) | Moduladores alostéricos de receptores de acetilcolina nicotínicos | |
| CL2018001089A1 (es) | Sales de valbenazina y polimorfos de las mismas. | |
| MX2019007587A (es) | Composicion oftalmica para el tratamiento de la enfermedad del ojo seco. | |
| CO2019002889A2 (es) | Tratamientos de combinación que comprenden la administración de imidazopirazinonas | |
| MX2018003388A (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| CL2019001891A1 (es) | Derivados de bis-heteroarilo bicíclicos como moduladores de agregación de proteínas. | |
| ECSP20042640A (es) | Derivados de indol 1, 3, 4, 5-tetrahidro-2h-pirido [4,3-b] para el tratamiento, alivio o prevención de trastornos asociados con agregados de tau como la enfermedad de alzheimer | |
| ECSP16072941A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| CR20130377A (es) | Métodos y productos de fármaco para tratar enfermedad de alzheimer | |
| GT201300324A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a | |
| CR20170187A (es) | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer | |
| BR112017007063A2 (pt) | ?composições e métodos para o tratamento de insônia? | |
| MX2024010721A (es) | Formulaciones topicas que contienen ciclosporina y usos de las mismas. | |
| MX2019000980A (es) | Compuestos y composiciones y usos de los mismos. | |
| CU20160151A7 (es) | 2-AMIN0-6-METI L-4,4a, 5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS | |
| CL2015000559A1 (es) | Compuestos derivados de 2-oxo-2,3-dihidro-indoles; su proceso de obtencion; composicion y combinacion farmaceutica que los comprende; y su uso para el tratamiento de trastornos del snc que son sintomas positivos o negativos de la esquizofrenia, el abuso de sustancias, la adiccion a alcohol y las drogas, enfermedad de alzheimer, enfermedad de parkinson, entre otras. | |
| DOP2019000112A (es) | PIRIDO[3,4-b]INDOLES SUSTITUIDOS PARA TRATAMIENTO DE LOS TRASTORNOS DE LOS CARTÍLAGOS | |
| CL2017000382A1 (es) | Compuestos bicíclicos sustituidos | |
| CO2017003321A2 (es) | Inhibidores de gingipaina de lisina | |
| EA201691567A1 (ru) | Способы лечения легких травм головного мозга | |
| MX2017001603A (es) | Derivados de piperazina como moduladores de los receptores x del higado. | |
| MX2018002446A (es) | Compuestos heterociclicos fusionados como moduladores s1p. | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 |